NASDAQ · Biotechnology
MGTX (MGTX) Stock
$14.06
-0.92%
NASDAQ: MGTX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?
Zacks · Jul 8, 2026
RBC Capital Adjusts MeiraGTx Price Target to $26 From $25, Maintains Outperform Speculative Risk Rating
MT Newswires · Jul 8, 2026
Top Midday Gainers
MT Newswires · Jul 7, 2026
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
GlobeNewswire · Jul 7, 2026
Can MeiraGTx Holdings PLC (MGTX) Stock Double? Cash Runway Offers a Hint
Insider Monkey · May 20, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held17.12%
Institutions Held61.14%
Institutions Float Held73.77%
Peer Comparison
About MGTX
MGTX is led by CEO Alexandria Forbes, employs 375 people, headquartered in US, publicly traded since 2018.
MGTX stock trades at $14.06 with a market capitalization of $1.30B. The stock is valued at a price-to-earnings (P/E) ratio of 19.70, price-to-book of 6.35, price-to-sales of 3.49. Over the past 52 weeks the stock has ranged between $6.62 and $15.35, and currently trades 8.4% below its 52-week high.
On profitability, MGTX generates a return on equity (ROE) of 284.38% — well above the market average, a sign of a high-quality business, return on capital employed of 54.39%, an operating margin of -130.86%, a net profit margin of 19.87%.